Capricor Therapeutics (CAPR) Notes Payables (2013 - 2021)

Capricor Therapeutics (CAPR) recorded quarterly Notes Payables of $282691.0 in Q1 2021, up 14.59% quarter-over-quarter from $246689.0 in Q4 2020.

Capricor Therapeutics (CAPR) Notes Payables (2013 - 2021) Analysis & Trends

Capricor Therapeutics' Notes Payables history runs 3 years deep, the most recent figure standing at $282691.0 for Q1 2021.

In Q1 2021, Notes Payables changed N/A year-over-year to $282691.0; the TTM figure through Mar 2021 stood at $282691.0 (changed N/A YoY), while the FY2020 annual figure was $246689.0, changed N/A from the prior year.
Notes Payables was $282691.0 for Q1 2021 at Capricor Therapeutics, up from $246689.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $282691.0 in Q1 2021 to a low of $139927.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Capricor Therapeutics	1.53 Bn	1.26 Bn	-

Download Data